Press coverage about Medpace (NASDAQ:MEDP) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Medpace earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.3164602137039 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Free Post Earnings Research Report: Medpace’ EPS Soared 92% (finance.yahoo.com)
- Medpace Holdings, Inc. (MEDP) Receives Consensus Rating of “Hold” from Brokerages (americanbankingnews.com)
- Medpace Holdings, Inc. Announces Pricing of Secondary Offering of Common Stock by Selling Shareholder (markets.financialcontent.com)
- Medpace Holdings, Inc. breached its 50 day moving average in a Bearish Manner : MEDP-US : November 30, 2017 (finance.yahoo.com)
Medpace (NASDAQ MEDP) opened at $33.66 on Thursday. Medpace has a 1-year low of $21.76 and a 1-year high of $39.64. The company has a market cap of $1,247.69, a price-to-earnings ratio of 22.58, a P/E/G ratio of 1.70 and a beta of -0.96. The company has a current ratio of 0.68, a quick ratio of 0.68 and a debt-to-equity ratio of 0.36.
Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, October 30th. The company reported $0.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.04. Medpace had a net margin of 6.44% and a return on equity of 10.00%. The business had revenue of $98.68 million during the quarter, compared to analysts’ expectations of $96.84 million. During the same quarter in the prior year, the company posted $0.40 earnings per share. The firm’s revenue was up 4.1% on a year-over-year basis. analysts forecast that Medpace will post 1.5 EPS for the current fiscal year.
MEDP has been the subject of several research reports. Zacks Investment Research downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. Raymond James Financial initiated coverage on shares of Medpace in a report on Friday, September 29th. They set a “market perform” rating for the company. William Blair cut shares of Medpace from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 1st. They noted that the move was a valuation call. Jefferies Group increased their target price on shares of Medpace from $34.00 to $38.00 and gave the stock a “hold” rating in a report on Wednesday, November 1st. Finally, Robert W. Baird restated a “hold” rating and set a $32.00 target price on shares of Medpace in a report on Monday, October 9th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $36.60.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Medpace (MEDP) Share Price” was posted by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.thestockobserver.com/2017/12/07/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-medpace-medp-share-price.html.
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.